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Abstract
© 2017 The  Author(s).  Platelet-driven  reduction  in  blood  clot  volume (clot  contraction  or
retraction) has been implicated to play a role in hemostasis and thrombosis. Although these
processes are often linked with inflammation, the role of inflammatory cells in contraction of
blood clots and thrombi has not been investigated. The aim of this work was to study the
influence of activated monocytes on clot contraction. The effects of monocytes were evaluated
using a quantitative optical tracking methodology to follow volume changes in a blood clot
formed in vitro. When a physiologically relevant number of isolated human monocytes pre-
activated with phorbol-12-myristate-13-acetate (PMA) were added back into whole blood, the
extent and rate of clot contraction were increased compared to addition of non-activated cells.
Inhibition of tissue factor expression or its inactivation on the surface of PMA-treated monocytes
reduced the  extent  and rate  of  clot  contraction  back  to  control  levels  with  non-activated
monocytes. On the contrary, addition of tissue factor enhanced clot contraction, mimicking the
effects of tissue factor expressed on the activated monocytes. These data suggest that the
inflammatory cells through their expression of tissue factor can directly affect hemostasis and
thrombosis by modulating the size and density of intra- and extravascular clots and thrombi.
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